Extremely large outlier treatment effects may be a footprint of bias in trials from less developed countries: randomized trials of gabapentinoids JOURNAL OF CLINICAL EPIDEMIOLOGY Desai, K., Carroll, I., Asch, S., Hernandez-Boussard, T., Ioannidis, J. A. 2019; 106: 80–87

View details for DOI 10.1016/j.jclinepi.2018.10.012

View details for Web of Science ID 000457818700010